

---

## REFERENCES

1. Pascolini D and Mariotti SP "Global estimates of visual impairment: 2010." *Br J Ophthalmol*, 2012, 96 (5), 614-618.
2. Lansingh V. C & Carter M. J. Use of Global Visual Acuity Data in a time trade-off approach to calculate the cost utility of cataract surgery. *Arch Ophthalmol*, 2009, 127(9), 1183.
3. Neena J, Rachel J, Praveen V, Murthy GVS. Rapid Assessment of Avoidable Blindness in India Study Group. *PLoSOne*. 2008; 3(8):e2867. Cross Ref Medline.
4. Kyselova Z, Stefek M, and Bauer V. "Pharmacological prevention of diabetic cataract." *J Diabetes Complications*, 2004, 18 (2), 129-140.
5. Obrosova I. G, Chung S. S & Kador P. F. Diabetic cataracts: mechanisms and management. *Diabetes Metab Res Rev*, 2010. 26(3), 172-180.
6. Negahban K, Chern K. Cataracts associated with systemic disorders and syndromes. *Curr Opin Ophthalmol*. 2002;13:419–422.
7. Olson R. J, Mamalis N, Werner L, Apple D. J. Cataract treatment in the beginning of the 21st century. *Am J Ophth*, 2003,136: 146 - 154.

8. Willcox J.K, Ash S.L. Antioxidants and prevention of chronic disease - *Crit Rev Food Sci Nutr*, 2004, 44, 275-295.
9. Halliwell B, Gutteridge J.M.C & Cross C.E. Free radicals, Antioxidants and Human Diseases: Where are we now? *J Lab Clin Med*, 1992, 119, 598-620.
10. Halliwell B, S. Chirico Lipid peroxidation: its mechanism, measurement and significance. *Am J Clin Nutr*, 1993, 57, 715s-724s.
11. Caberera M.P, Chihuailaf R.H. Antioxidants and the integrity of ocular tissues, *Vet Med Int*, 2011, 1-8.
12. Punchard N. A & Kelly F. J. *Free radicals: a practical approach*, 1996. 119- 157, Oxford University Press.
13. Taylor A, Jacques P. F & Epstein E. M. Relations among aging, antioxidant status, and cataract. *Am J Clin Nutr*, 1995, 62(6), 1439S-1447S.
14. Boscia F, Grattagliano I, Vendemiale G, Micelli-Ferrari T & Altomare E. Protein oxidation and lens opacity in humans. *Invest Ophthalmol Vis Sci*, 2000, 41(9), 2461-2465.
15. Varma S.D. Scientific basis for medical therapy of cataracts by antioxidants. *Am J Clin Nutr*, 1991. 53(1), 335S-345S.

16. Čejková J, Štípek S, Crkovska J, Ardan T, Platenik J, Čejka C & Midelfart A. UV rays, the prooxidant/antioxidant imbalance in the cornea and oxidative eye damage. *Physiol Res*, 2004, 53, 1-10.
17. Araki N, Ueno N, Chakrabarti B, Morino Y & Horiuchi S. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. *Journal of Biological Chemistry*, 1992, 267(15), 10211-10214.
18. Duhaiman A. S. Glycation of human lens proteins from diabetic and (nondiabetic) senile cataract patients. *Glycoconj J*, 1995. 12(5), 618-621.
19. Baynes J. W. Role of oxidative stress in development of complications in diabetes. *Diabetes*, 1991. 40(4), 405-412.
20. Cameron N. E, Cotter M. A & Archibald V. Chronic N-acetyl-L-cysteine treatment prevents impaired endothelium-dependent relaxation and improves peripheral nerve blood flow and conduction in diabetic rats. *Eur J Clin Invest*, 1995. 25, A9.
21. Di Mario U & Pugliese G. 15<sup>th</sup> Golgi lecture: from hyperglycaemia to the dysregulation of vascular remodelling in diabetes. *Diabetologia*, 2001, 44(6), 674-692.

22. Nishikawa T, Edelstein D, Du X. L, Yamagishi S. I, Matsumura T, Kaneda Y & Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. *Nature*, 2000, 404(6779), 787-790.
23. Seo H. G, Nishinaka T & Yabe-Nishimura C. Nitric oxide up-regulates aldose reductase expression in rat vascular smooth muscle cells: a potential role for aldose reductase in vascular remodeling. *Molecular pharmacology*, 2000. 57(4), 709-717.
24. Buchanan J. D & Armstrong D. A. The radiolysis of glyceraldehyde-3-phosphate dehydrogenase. *Int J Radiat Biol*, 1978. 33(5), 409-418.
25. Marin P, Maus M, Bockaert J, Glowinski J & Premont J. Oxygen free radicals enhance the nitric oxide-induced covalent NAD<sup>(+)</sup>- linkage to neuronal glyceraldehyde-3-phosphate dehydrogenase. *Biochem J*, 1995. 309, 891-898.
26. Rivera-Nieves J, Thompson W. C, Levine R. L, & Moss J. Thiols mediate superoxide- dependent NADH modification of glyceraldehyde-3-phosphate dehydrogenase. *Journal of Biological Chemistry*, 1999, (28), 19525-19531.

27. Salvemini D & Cuzzocrea S. Oxidative stress in septic shock and disseminated intravascular coagulation. *Free Radic Biol Med*, 2002, 33(9), 1173-1185.
28. Baynes J. W & Thorpe S. R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. *Diabetes*, 1999, 48(1), 1-9.
29. Nishikawa T, Edelstein, D, & Brownlee M. The missing link: a single unifying mechanism for diabetic complications. *Kidney Int Suppl*, 2000. 58, S26-S30.
30. Chang K. C, Paek K. S, Kim, H. J, Lee Y. S, Yabe-Nishimura C, & Seo H. G. Substrate-induced up-regulation of aldose reductase by methylglyoxal, a reactive oxoaldehyde elevated in diabetes. *Molecular pharmacology*, 2002, 61(5), 1184-1191.
31. González, R. G, Barnett, P, Aguayo, J, Cheng, H. M & Chylack, L. T. Direct measurement of polyol pathway activity in the ocular lens. *Diabetes*, 1984, 33(2), 196-199.
32. Morrison A. D, Clements Jr, R. S, Travis S. B, Oski F & Winegrad A. I. Glucose utilization by the polyol pathway in human erythrocytes. *Biochem Biophys Res Commun*, 1970, 40(1), 199-205.

- 
33. Kinoshita J. H. A thirty year journey in the polyol pathway. *Exp Eye Res*, 1990, 50(6), 567-573.
  34. Chung S. S, Ho E. C, Lam K. S & Chung S. K. Contribution of polyol pathway to diabetes-induced oxidative stress. *J Am Soc Nephrol* , 2003. 14(suppl 3), S233-S236.
  35. Ponnachan P T, Paulose C S, Panikkar R Effect of leaf extract of *Aegle marmelos* in diabetic rats, *Indian J. Exp. Biol* , 31: 345-347
  36. Ahmad M.S & Ahmed N. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. *The Journal of nutrition*, 2006, 136(3), 796S-799S.
  37. Mathew PT & Augusti KT, Studies on the effect of allicin (diallyl disulphide- oxide) on alloxan diabetes- hypoglycemic action and enhancement of serum insulin effect and glycogen synthesis. *Indian J. Biochem. Biophys.* 1973,10: 209. (0137) 25.
  38. Suryanarayana P, Kumar P. A, Saraswat M, Petrash J. M, & Reddy G. B. Inhibition of aldose reductase by tannoid principles of *Emblica officinalis*: implications for the prevention of sugar cataract. *Mol. Vis*, 2004; 10: 148-154

39. Prince P. S. M, Menon V. P & Pari L. Hypoglycaemic activity of *Syzigium cumini* seeds: effect on lipid Peroxidation in alloxan diabetic rats. *J Ethnopharmacol*, 1998 *61*: 1-7.
40. Tiwari A. K & Madhusudanarao J. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. *Current science*, 2002, 83.
41. Brownlee M. The pathobiology of diabetic complications a unifying mechanism. *Diabetes*, 2005, *54*(6), 1615-1625.
42. Bron, A. J, Brown N. A, Harding J. J, & Ganea, E. The lens and cataract in diabetes. *Int Ophthalmol Clin*, 1998, *38*(2), 37-67.
43. Pollreisz A & Schmidt-Erfurth U. Diabetic cataract—pathogenesis, epidemiology and treatment. *J Ophthalmol*, 2010.
44. Obrosova I. G, Chung S. S & Kador P. F. Diabetic cataracts: mechanisms and management. *Diabetes Metab Res Rev*, 2010. *26*(3), 172-180.
45. Brownlee M. The pathobiology of diabetic complications a unifying mechanism. *Diabetes*, 2005. *54*(6), 1615-1625.
46. Halliwell B & Gutteridge J. The antioxidants of human extracellular fluids. *Arch Biochem Biophys*, 1990. *280*(1), 1-8.

47. Bhuyan K. C, Bhuyan D. K & Podos S. M. Lipid peroxidation in cataract of the human. *Life sciences*, 1986. 38(16), 1463-1471.
48. Spector A, & Garner W. H. Hydrogen peroxide and human cataract. *Exp Eye Res*, 1981. 33(6), 673-681.
49. Ramachandran S, Morris S. M, Devamanoharan P, Henein M & Varma S. D. Radio-isotopic determination of hydrogen peroxide in aqueous humor and urine. *Exp Eye Res*, 1991. 53(4), 503-506.
50. Jernigan Jr. H. M, Fukui H. N, Goosey J. D, & Kinoshita J. H. Photodynamic effects of rose bengal or riboflavin on carrier-mediated transport systems in rat lens. *Exp Eye Res*, 1981. 32(4), 461-466.
51. Garner M. H, Roy D & Spector A. Immunochemical characterization of the main intrinsic proteins of the human lens membrane. *Exp Eye Res*, 1982. 34(5), 781-788.
52. Spector A, Wang G. M, Wang R. R, Garner W. H & Moll H. The prevention of cataract caused by oxidative stress in cultured rat lenses in H<sub>2</sub>O<sub>2</sub> and photochemically induced cataract. *Curr Eye Res*, 1993. 12(2), 163-179.
53. McNamara M & Augusteyn R. C. The effects of hydrogen peroxide on lens proteins: a possible model for nuclear cataract. *Exp Eye Res*, 1984; 38(1), 45-56.



- 
54. Zigler JS, Huang QI, Du Xy. Oxidative modification of lens crystallins by H<sub>2</sub>O<sub>2</sub> and chelated iron. *Free Radic Biol Med*, 1989; 7:499,S05
  55. Zigler Jr, J. S., Jernigan Jr, H. M., Garland, D & Reddy V. N. The effects of “oxygen radicals” generated in the medium on lenses in organ culture: inhibition of damage by chelated iron. *Arch Biochem Biophys*, 1985, 241(1), 163-172.
  56. Garner W. H, Garner M. H & Spector A. H<sub>2</sub>O<sub>2</sub>-induced uncoupling of bovine lens Na<sup>+</sup>, K<sup>+</sup>-ATPase. *Proceedings of the National Academy of Sciences*, 1983. 80(7), 2044-2048.
  57. Parveen A, Lens Enzyme Profiles in Cataract, *PhD Thesis*, University of Pune, 1996.
  58. Nahid H, Role of antioxidants in experimental cataract, *PhD Thesis*, University of Pune, 1998
  59. Spector A. Oxidative stress-induced cataract: mechanism of action. *FASEB J*, 1995, 9(12), 1173-1182.
  60. Hunt J. V, Dean R. T & Wolff S. P. Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. *Biochem. J*, 1988. 256, 205-212.

61. Sakurai T & Tsuchiya S. Superoxide production from nonenzymatically glycosylated protein. *FEBS Lett*, 1988. 236(2), 406-410.
62. Wolf S. P & Dean R. T. Glucose autooxidation and protein modification. *Biochem J*, 1987; 245, 243-250.
63. Lin J H & Yamazaki M. Role of P-glycoprotein in pharmacokinetics. *Clin pharmacokin*, 2003, 42(1), 59-98
64. Stitt A. W. The Maillard reaction in eye diseases. *Ann N Y Acad Sci*, 2005. 1043(1), 582-597.
65. Hong S. B, Lee K. W, Handa J. T, & Joo C. K. Effect of Advanced Glycation End Products on Lens Epithelial Cells in Vitro. *Biochem Biophys Res Commun*, 2000. 275(1), 53-59.
66. Obrosova I. G. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. *Antioxid Redox Signal*, 2005, 7(11-12), 1543-1552.
67. Ookawara T, Kawamura N, Kitagawa Y & Taniguchi N. Site-specific and random fragmentation of Cu, Zn-superoxide dismutase by glycation reaction- Implication of reactive oxygen species. *Journal of Biological Chemistry*, 1992. 267(26), 18505-18510.

- 
68. Reddy V. N, Kasahara E, Hiraoka M, Lin L. R & Ho Y. S. Effects of variation in superoxide dismutases (SOD) on oxidative stress and apoptosis in lens epithelium. *Exp Eye Res*, 2004, 79(6), 859-868.
69. Rolo A. P, & Palmeira C. M. Diabetes and mitochondrial function: role of hyperglycemia and oxidative stress. *Toxicol Appl Pharmacol*, 2006. 212(2), 167-178.
70. Maritim A. C, Sanders R. A & Watkins J. Diabetes, oxidative stress, and antioxidants: a review. *J Biochem Mol Toxicol*, 2003. 17(1), 24-38.
71. Varma SD, Kumar S, Light Induced damage to ocular lens cation pump, *Acad.Sci.USA*,1979, 76: 504–3506 .
72. Hegde K & Varma S. D. Protective effect of ascorbate against oxidative stress in the mouse lens. *Biochim Biophys Acta*, 2004. 1670(1), 12-18.
73. Devamanoharan P. S, Henein M, Morris S, Ramachandran S, Richards R. D & Varma S. D. Prevention of selenite cataract by vitamin C. *Exp Eye Res*, 1991; 52(5), 563-568.
74. Heath H & Fiddick R. The ascorbic acid-dependent oxidation of reduced nicotinamide-adenine dinucleotide by ciliary and retinal microsomes. *Biochem. J*, 1965 94, 114-119.

75. Taylor A, Jacques P. F, Nadler D, Morrow F, Sulsky S. I & Shepard D. Relationship in humans between ascorbic acid consumption and levels of total and reduced ascorbic acid in lens, aqueous humor, and plasma. *Curr Eye Res*, 1991; 10(8), 751-759.
76. Taylor A, Jacques P. F, Nowell T, Perrone G, Blumberg J, Handelman G & Nadler D. Vitamin C in human and guinea pig aqueous, lens and plasma in relation to intake. *Curr Eye Res*, 1997; 16(9), 857-864.
77. Ohta Y, Niwa T & Yamasaki T. Effect of prolonged marginal ascorbic acid deficiency on lenticular levels of antioxidants and lipid peroxide in guinea pigs. *Int J Vitam Nutr Res Suppl*, 2001; 71(2), 103-109.
78. Berger D, Shepard F, Morrow A, Taylor; Relationships between dietary intake and tissue levels of reduced and total vitamin C in the nonscorbutic guinea pig. *J. Nutr*, 1989; 119, 734-740.
79. Yu B. P. Cellular defenses against damage from reactive oxygen species. *Physiol Rev Suppl*. 1994; 74(1), 139.
80. Halliwell B & Gutteridge J. Role of free radicals and catalytic metal ions in human disease: an overview. *Methods Enzymol*, 1989; 186, 1-85.

- 
81. Van der Pols J. C. A possible role for vitamin C in age-related cataract. In *Proc Nutr Soc*, 1999, May. Vol. 58,. 295-301. Cambridge University Press.
  82. Sasaki H, Giblin F. J, Winkler B. S, Chakrapani B, Leverenz V & Shu C. C. A protective role for glutathione-dependent reduction of dehydroascorbic acid in lens epithelium. *Invest Ophthalmol Vis Sci*, 1995. 36(9), 1804-1817.
  83. Spector A, Ma W & Wang R. R. The aqueous humor is capable of generating and degrading H<sub>2</sub>O<sub>2</sub>. *Invest Ophthalmol Vis Sci*, 1998. 39(7), 1188-1197
  84. Chow C. K. Vitamin E and oxidative stress. *Free Radical Biology and Medicine*, 1991; 11(2), 215-232.
  85. Oberley L. W. Free radicals and diabetes. *Free Radical Biology and Medicine*, 1988; 5(2), 113-124.
  86. Weber P, Bendich A & Machlin L. J. Vitamin E and human health: rationale for determining recommended intake levels. *Nutrition*, 1997. 13(5), 450-460.
  87. Asayama K, Uchida N, Nakane T, Hayashibe H, Dobashi K, Amemiya S, Kato K, Nakazawa S: Antioxidants in the serum of children with insulin-dependent diabetes mellitus. *Diabetes* ; 1994, 43:1010-1014,

88. Garg M. C, Ojha S & Bansal D. D. Antioxidant status of streptozotocin diabetic rats. *Indian J Exp Biol*, 1996; 34(3), 264-266.
89. Palmer A. M, Thomas C. R, Gopaul N, Dhir S, Änggård E, Poston L & Tribe R. M. Dietary antioxidant supplementation reduces lipid peroxidation but impairs vascular function in small mesenteric arteries of the streptozotocin-diabetic rat. *Diabetologia*, 1998. 41(2), 148-156.
90. Çınar M. G, Ülker S, Alper G. U. L & Evinc A. Effect of Dietary Vitamin E Supplementation on Vascular Reactivity of Thoracic Aorta in Streptozotocin-Diabetic Rats. *Pharmacology*, 2001; 62(1), 56-64.
91. Martinoli L, Di Felice M, Seghieri G, Ciuti M, De Giorgio L. A, Fazzini A & Franconi F. Plasma retinol and alpha-tocopherol concentrations in insulin-dependent diabetes mellitus: their relationship to microvascular complications. *Int J Vitam Nutr Res Suppl*. 1992; 63(2), 87-92.
92. Powers S. K. & Lennon S. L. Analysis of cellular responses to free radicals: focus on exercise and skeletal muscle. *Proc Nutr Soc*, 1999. 58(04), 1025-1033.

93. Chihuailaf R. H, Contreras P. A & Wittwer F. G. Pathogenesis of oxidative stress: Consequences and evaluation in animal health. *Veterinaria México*, 2002; 33(3), 265-284.
94. Ross W. M, Creighton M. O & Trevithick J. R. Radiation cataractogenesis induced by neutron or gamma irradiation in the rat lens is reduced by vitamin E. *Scanning Microsc*, 1990; 4(3), 641-9.
95. Nagata M, Kojima M & Sasaki K. Effect of vitamin E eye drops on naphthalene-induced cataract in rats. *J Ocul Pharmacol Ther*, 1999; 15(4), 345-350.
96. Ohta Y, Yamasaki T, Niwa T, Majima Y & Ishiguro I. Preventive effect of topical vitamin E-containing liposome instillation on the progression of galactose cataract. Comparison between 5-week-and 12-week-old rats fed a 25% galactose diet. *Exp Eye Res*, 1999; 68(6), 747-755.
97. Leske M. C, Chylack Jr L. T, He Q, Wu S. Y, Schoenfeld E, Friend J & Wolfe J. Antioxidant vitamins and nuclear opacities: the longitudinal study of cataract. *Ophthalmology*, 1998; 105(5), 831-836.
98. Yeum K J, Shang F M, Schalch W M, Russell R M and Taylor A. Fat-soluble nutrient concentrations in different layers of human cataractous lens, *Curr Eye Res*, 1999; 19, 502-505.

- 
99. Chasan-Taber L, Willett W. C, Seddon J. M, Stampfer M. J, Rosner B, Colditz G. A & Hankinson S. E. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. *Am J Clin Nutr*, 1999 ;70(4), 509-516.
100. Hankinson S. E, Stampfer M. J, Seddon J. M, Colditz G. A, Rosner B, Speizer F. E & Willett W. C. Nutrient intake and cataract extraction in women: a prospective study. *BMJ*, 1992; 305(6849), 335.
101. Brown L, Rimm E. B, Seddon J. M, Giovannucci E. L, Chasan-Taber L, Spiegelman D & Hankinson S. E. A prospective study of carotenoid intake and risk of cataract extraction in US men. *Am J Clin Nutr*, 1999; 70(4), 517-524.
102. Moeller S. M, Jacques P. F & Blumberg J. B. The potential role of dietary xanthophylls in cataract and age-related macular degeneration. *J Am Coll Nutr*, 2000; 19(sup5), 522S-527S.
103. Wu G, Fang Y. Z, Yang S, Lupton J. R & Turner N. D. Glutathione metabolism and its implications for health. *The Journal of nutrition*, 2004; 134(3), 489-492.
104. Obrosova I. G & Stevens M. J. Effect of dietary taurine supplementation on GSH and NAD (P)-redox status, lipid



- peroxidation, and energy metabolism in diabetic precataractous lens. *Invest Ophthalmol Vis Sci*, 1999; 40(3), 680-688.
105. Kannan R, Tang D, Mackic J. B, Zlokovic B. V & Fernandez-Checa J. C. A simple technique to determine glutathione (GSH) levels and synthesis in ocular tissues as GSH-bimane adduct: application to normal and galactosemic guinea-pigs. *Exp Eye Res*, 1993. 56(1), 45-50.
106. Taylor A, Jacques P. F & Epstein E. M. Relations among aging, antioxidant status, and cataract. *Am J Clin Nutr*, 1995; 62(6), 1439S-1447S.
107. Zhang S, Chai F. Y, Yan H, Guo Y & Harding J. J. Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. *Mol vis*, 2008;14, 862.
108. Sundaram M, Kavookjian J, Patrick J. H, Miller L. A, Madhavan S. S & Scott V. G. Quality of life, health status and clinical outcomes in Type 2 diabetes patients. *Qual Life Res*, 2007; 16(2), 165-177.
109. Ganea E & Harding J. J. Glutathione-related enzymes and the eye. *Curr Eye Res*, 2006; 31(1), 1-11.
110. Harding, J. J. Free and protein-bound glutathione in normal and cataractous human lenses. *Biochem. J*, 1970; 117, 957-960.

111. George S, Jyothi M, Mathew B, Shashidhar S. Changes in glutathione, glutathione-linked enzymes and hexose monophosphate shunt enzymes in senile cataract. *Ind J Physiol Pharmacol*. 2003 ; 47:191-6.
112. Donma O, Yorulmaz, E. Ö, Peke H, & Suyugül, N. Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. *Curr eye res*, 2002. 25(1), 9-16.
113. Doganay S, Turkoz Y, Evereklioglu C, Er H, Bozaran M, & Ozerol E. Use of caffeic acid phenethyl ester to prevent sodium-selenite-induced cataract in rat eyes. *J Cataract Refract Surg*, 2002. 28(8), 1457-1462.
114. Doganay S, Borazan M, Iraz M & Cigremis Y. The effect of resveratrol in experimental cataract model formed by sodium selenite. *Curr eye res*, 2006; 31(2), 147-153.
115. Ortwerth B. J & Olesen P. R. Glutathione inhibits the glycation and crosslinking of lens proteins by ascorbic acid. *Exp eye res*, 1988; 47(5), 737-750.
116. Nagaraj R. H, Prabhakaram M, Ortwerth B. J & Monnier V. M. Suppression of pentosidine formation in galactosemic rat lens by an inhibitor of aldose reductase. *Diabetes*, 1994; 43(4), 580-586

- 
117. Cejkova J, Stipek S, Crkovska J & Ardan T. Changes of superoxide dismutase, catalase and glutathione peroxidase in the corneal epithelium after UVB rays. Histochemical and biochemical study. 2000
118. Čejková J., Štípek S, Crkovska J, Ardan T, Platenik J, Čejka C & Midelfart, A. UV rays, the prooxidant/antioxidant imbalance in the cornea and oxidative eye damage. *Physiol Res*, 2004. 53, 1-10.
119. Bilgihan A, Bilgihan K, Yis Ö, Sezer C, Akyol G & Hasanreisoglu B. Effects of topical vitamin E on corneal superoxide dismutase, glutathione peroxidase activities and polymorphonuclear leucocyte infiltration after photorefractive keratectomy. *Acta Ophthalmol Scand*, 2003. 81(2), 177-180.
120. Ozmen B, Ozmen D, Turgan N, Habif S, Mutaf I & Bayindir O. Association between homocysteinemia and renal function in patients with type 2 diabetes mellitus *Ann Clin Lab Sci* 2002; 32(3),279-286.
121. Satıcı A, Guzey M, Gurler B Vural, H, & Gurkan, T. Malondialdehyde and antioxidant enzyme levels in the aqueous humor of rabbits in endotoxin-induced uveitis. *Eur J Ophthalmol*; 2003; Vol. 13 no. 9/10, 779-783
122. Obara Y. [The oxidative stress in the cataract formation]. *Nippon Ganka Gakkai Zasshi*, 1995; 99(12), 1303-1341.

- 
123. Khanna P, Wang L, Perez-Polo R. J & Ansari N H. Oxidative defense enzyme activity and mRNA levels in lenses of diabetic rats. *J of toxicol and environ health*, 1997. 51(6), 541-555.
124. Yan H & Harding J. Glycation-induced inactivation and loss of antigenicity of catalase and superoxide dismutase. *Biochem. J*, 1997. 328, 599-605.
125. Özmen, D., Özmen B, Erkin E, Güner İ, Habif S, Bayındır O & Onağ A. Lens superoxide dismutase and catalase activities in diabetic cataract. *Turkish Journal of Endocrin and Metab*, 2000. 4(1), 1-4.
126. Fridovich I. Superoxide radical and superoxide dismutases. *Annu Rev Biochem*, 1995. 64(1), 97-112.
127. Behndig, A., Karlsson, K., Johansson, B. O., Brännström, T & Marklund, S. L. Superoxide dismutase isoenzymes in the normal and diseased human cornea. *Invest Ophthalmol Vis Sci*, 2001; 42(10), 2293-2296.
128. Scharf J & Dovrat A. Superoxide dismutase molecules in human cataractous lenses. *Ophthalm res*, 1986; 18(6), 332-337.
129. Olofsson, E. M., Marklund, S. L., & Behndig, A. Enhanced diabetes-induced cataract in copper-zinc superoxide dismutase-null mice. *Invest ophthalmol vis sci*, 2009; 50(6), 2913-2918.

130. Olofsson, E. M., Marklund, S. L., & Behndig, A. Glucose-induced cataract in CuZn-SOD null lenses: An effect of nitric oxide. *Free Radical Biology and Medicine*, 2007; 42(7), 1098-1105.
131. Van Heyningen R & Pirie, A. Reduction of glutathione coupled with oxidative decarboxylation of malate in cattle lens. *Biochem Jour*, 1953; 53(3), 436.
132. McCay P. B, Gibson D. D, Kuo-Lan F & K Roger H. Effect of glutathione peroxidase activity on lipid peroxidation in biological membranes. *Biochim Biophys Acta* 1976; 431(3), 459-468.
133. Reddy V. N. Metabolism of glutathione in the lens. *Exp eye res*, 1971; 11(3), 310-328.
134. Meloni T, Carta F, Forteleoni G, Carta, A, Ena F & Meloni G. F. Glucose 6-phosphate dehydrogenase deficiency and cataract of patients in northern Sardinia. *Am J of ophthal*, 1990; 110(6), 661-664.
135. Jedziniak J. A, Kinoshita J. H, Yate, E. M, Hocker L. O & Benedek G. B. On the presence and mechanism of formation of heavy molecular weight aggregates in human normal and cataractous lenses. *Exp eye res*, 1973; 15(2), 185-192.

- 
136. Čejková J, Vejražka M, Pláteník J & Štípek S. Age-related changes in superoxide dismutase, glutathione peroxidase, catalase and xanthine oxidoreductase/xanthine oxidase activities in the rabbit cornea. *Exp Gerontol*, 2004; 39(10), 1537-1543.
137. Ringvold A, Anderssen E & Kjønniksen I. Distribution of ascorbate in the anterior bovine eye. *Invest ophthalmol visu sci*, 2000; 41(1), 20-23.
138. Godin D. V, Wohaieb S. A, Garnett M. E & Goumeniouk A. D. Antioxidant enzyme alterations in experimental and clinical diabetes. *Mol Cell Biochem*, 1988, 84(2), 223-231.
139. Özmen B, Özmen D, Erkin E, Güner I, Habif S & Bayındır O. Lens superoxide dismutase and catalase activities in diabetic cataract. *Clinical biochemistry*, 2002; 35(1), 69-72.
140. Brownlee M. Advanced glycation end products in diabetic complications. *Curr Opin Endocrin Diabetes*, 1996; 3:291–297
141. Monnier V. M, Sell D. R, Nagaraj R. H, Miyata S, Grandhee S, Odetti P & Ibrahim S. A. Maillard reaction-mediated molecular damage to extracellular matrix and other tissue proteins in diabetes, aging, and uremia. *Diabetes*, 1992; 41(Supplement 2), 36-41.
142. Kowluru, R. A, Kern T. S & Engerman R. L. Abnormalities of retinal metabolism in diabetes or experimental galactosemia. IV. Antioxidant

- defense system. *Free Radical Biology and Medicine*, 1996; 22(4), 587-592.
143. Wohaieb S. A. & Godin D. V. Alterations in free radical tissue-defense mechanisms in streptozocin-induced diabetes in rat: effects of insulin treatment. *Diabetes*, 1987; 36(9), 1014-1018.
144. Westwood M. E & Thornalley P. J. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. *Protein Chem*, 1995; 14(5), 359-372.
145. Lyons T. J, Silvestri G, Dunn J. A, Dyer D. G & Baynes J. W. Role of glycation in modification of lens crystallins in diabetic and nondiabetic senile cataracts. *Diabetes*, 1991; 40(8), 1010-1015.
146. Nagaraj R. H, Sell D. R, Prabhakaram M, Ortwerth B. J & Monnier V. M. High correlation between pentosidine protein crosslinks and pigmentation implicates ascorbate oxidation in human lens senescence and cataractogenesis. *Proc Natl Acad Sci*, 1991; 88(22), 10257-10261.

- 
147. Shamsi F. A, Sharkey E, Creighton D & Nagaraj R. H. Maillard reactions in lens proteins: methylglyoxal-mediated modifications in the rat lens. *Exp eye res*, 2000; 70(3), 369-380.
148. Kador P. F, Kinoshita J. H & Sharpless N. E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. *J Med Chem*, 1985; 28(7), 841-849.
149. Greene, Douglas A, Anders AF, Sima, Martin J. Stevens, Eva L, Feldman and Sarah A. Lattimer. "Complications: neuropathy, pathogenetic considerations. *Diabetes care*, 1992; 15, no. 12: 1902-1925.
150. Obrosova I, Faller A, Burgan J, Ostrow E & Williamson J. R. Glycolytic pathway, redox state of NAD (P)-couples and energy metabolism in lens in galactose-fed rats: effect of an aldose reductase inhibitor. *Curr eye res*, 1997; 16(1), 34-43.
151. HG Hers; *Biochim Biophys Acta*, 22 (1956), pp. 202–203.
152. Van Heyningen R. Formation of polyols by the lens of the rat with 'sugar' cataract. *Nature*, Lond, 1959; 184, p. 194.-195



153. Kinoshita J. H, Merola L. O & Tun, B. Changes in cation permeability in the galactose-exposed rabbit lens. *Exp eye res*, 1968; 7(1), 80-90.
154. Varma S. D & Kinoshita J. H. Inhibition of lens aldose reductase by flavonoids- their possible role in the prevention of diabetic cataracts. *Biochem Pharmacol*, 1976; 25(22), 2505-2513.
155. Varma S. D, Mizuno A & Kinoshita J. H. Diabetic cataracts and flavonoids. *Science*, 1977; 195(4274), 205-206.
156. Kinoshita J. H, Fukushi S, Kador P & Merola L. O. Aldose reductase in diabetic complications of the eye. *Metabolism*, 1979; 28(4), 462-469.
157. Kinoshita J. H, Kador P & Catiles M. Aldose reductase in diabetic cataracts. *Jama*, 1981; 246(3), 257-261.
158. Bhatnagar A & Srivastava S. K. Aldose reductase: congenial and injurious profiles of an enigmatic enzyme. *Biochem Med Metab Biol*, 1992, 48(2), 91-121.
159. Sheetz M. J & King G. L. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. *Jama*, 2002; 288(20), 2579-2588.

160. Gonzalez AM, Sohor M, McLean P. The effect of an aldose reductase inhibitor (sorbiniol) on the level of metabolites in lenses of diabetic rats. *Diabetes*, 1983; 32: 482–485.
161. Lee AY, Chung SS. Contributions of polyol pathway to oxidative stress in diabetic cataract. *FASEB J*, 1999; 13:23–30
162. Obrosova I, Cao X, Greene D. A & Stevens M. J. Diabetes-induced changes in lens antioxidant status, glucose utilization and energy metabolism: effect of DL- $\alpha$ -lipoic acid. *Diabetologia*, 1998, 41(12), 1442-1450.
163. Varma S. D & Kinoshita J. H. The absence of cataracts in mice with congenital hyperglycemia. *Exp eye res*, 1974; 19(6), 577-582.
164. Lee A. Y, Chung S. K & Chung S.S. Demonstration that polyol accumulation is responsible for diabetic cataract by the use of transgenic mice expressing the aldose reductase gene in the lens. *Proc Natl Acad Sci*, 1995; 92(7), 2780-2784.
165. Cheung A. K, Fung M. K, Lo A. C. Lam T. T, So K. F, Chung S. S & Chung S. K. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. *Diabetes*, 2005. 54(11), 3119-3125.

166. Pitts N. E, Vreeland F, Shaw G. L, Peterson M. J, Mehta D. J, Collier J & Gundersen K. Clinical experience with sorbinil-an aldose reductase inhibitor. *Metabolism*, 1986; 35(4), 96-100.
167. Stribling D. Clinical trials with aldose reductase inhibitors. *Exp eye res*, 1990; 50(6), 621-624.
168. Hotta N, Kakuta H, Ando F & Sakamoto N. Current progress in clinical trials of aldose reductase inhibitors in Japan. *Exp eye res*, 1990; 50(6), 625-628.
169. Kador P. F, Kinoshita J. H & Sharpless N. E. Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications. *J med chem*, 1985;28(7), 841-849.
170. Brownlee M, Vlassara H, Kooney A, Ulrich P & Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. *Science*, 1986; 232(4758), 1629-1632.
171. Khatami M, Suldan, Z, David I, Li W & Rockey J. H. Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. *Life sciences*, 1988; 43(21), 1725-1731.

172. Lewis B. S & Harding J. J. The effects of aminoguanidine on the glycation (non- enzymic glycosylation) of lens proteins. *Exp eye res*, 1990; 50(5), 463-467.
173. Swamy-Mruthinti S, Green K & Abraham E. C. Inhibition of cataracts in moderately diabetic rats by aminoguanidine. *Exp eye res*, 1996; 62(5), 505-510.
174. **Cotlier E.** Senile **cataract**: evidence for acceleration by diabetes and deceleration by salicylates. **1961**;1
175. Ajiboye R & Harding J. J. The non-enzymic glycosylation of bovine lens proteins by glucosamine and its inhibition by aspirin, ibuprofen and glutathione. *Exp eye res*, 1989; 49(1), 31-41.
176. Bucala R, Callati M, Manabe S, Cotlier E & Cerami A. Glucocorticoid-lens protein adducts in experimentally induced steroid cataracts. *Exp eye res*, 1985; 40(6), 853-863.
177. Rao G. N & Cotlier E. Aspirin prevents the nonenzymatic glycosylation and carbamylation of the human eye lens crystallins in vitro. *Biochem Biophys Res Commun*, 1988; 151(3), 991-996.
178. Swamy M. S & Abraham E. C. Inhibition of lens crystallin glycation and high molecular weight aggregate formation by aspirin in vitro and in vivo. *Invest Ophthalmol Vis Sci*, 1989; 30(6), 1120-1126.

- 
179. Crompton M, Rixon K. C & Harding J. J. Aspirin prevents carbamylation of soluble lens proteins and prevents cyanate-induced phase separation opacities in vitro: a possible mechanism by which aspirin could prevent cataract. *Exp eye res*, 1985; 40(2), 297-311.
180. Qin W, Smith J. B & Smith D. L. Reaction of aspirin with cysteinyl residues of lens  $\gamma$ -crystallins: a mechanism for the proposed anti-cataract effect of aspirin. *Biochim Biophys Acta*, 1993; 1181(2), 103-110.
181. Lin P. P, Barry R. C, Smith D. L & Smith J. B. In vivo acetylation identified at lysine 70 of human lens  $\alpha$ -crystallin. *Protein science*, 1998; 7(6), 1451-1457.
182. Harding J J, Blackytny R, Cataract : biochemistry, epidemiology and pharmacology. Chapman and Hall, London (1991) p.83–124.[3]; The lens in diabetes. *Eye*, 1993, 7,pp. 260
183. Gupta P. P, Pandey D. N, Pandey D. J et al. Aspirin in experimental cataractogenesis. *Ind J Med Res*, 1984; 80: 703–7
184. Crabbe M. J. C & Goode D. Aldose reductase: a window to the treatment of diabetic complication? *Prog Retin Eye Res*, 1998; 17(3), 313-383.

- 
185. Yabe-Nishimura, C. Aldose reductase in glucose toxicity: a potential target for the prevention of diabetic complications. *Pharmacol Rev*, 1998; 50(1), 21-34.
186. Srivastava S. K, Ramana K. V & Bhatnagar A. Role of aldose reductase and oxidative damage in diabetes and the consequent potential for therapeutic options. *Endo Rev*, 2005; 26(3), 380- 392.
187. Ramana K. V, Dixit B. L, Srivastava S, Balendiran G. K, Srivastava S. K & Bhatnagar A. Selective recognition of glutathiolated aldehydes by aldose reductase. *Biochemistry*, 2000; 39(40),12172-12180.
188. Dixit B. L, Balendiran G. K, Watowich S. J, Srivastava S, Ramana K. V, Petrash J. M & Srivastava S. K. Kinetic and structural characterization of the glutathione-binding site of aldose reductase. *J Biol Chem*, 2000; 275(28), 21587-21595.
189. Ruef J, Liu S. Q, Bode C, Tocchi M, Srivastava S, Runge M. S & Bhatnagar A. Involvement of aldose reductase in vascular smooth muscle cell growth and lesion formation after arterial injury. *Arterioscler Thromb Vasc Biol*, 2000; 20(7), 1745-1752.
190. Ramana K. V, Friedrich B, Srivastava S, Bhatnagar A & Srivastava S. K. Activation of nuclear factor- $\kappa$ B by hyperglycemia in vascular

- smooth muscle cells is regulated by aldose reductase. *Diabetes*, 2004; 53(11), 2910-2920.
191. Bailey C. J. Potential new treatments for type 2 diabetes. *Trends Pharmacol Sci* 2000; 21(7), 259-265.
192. Tiwari A. K & Madhusudanarao J. Diabetes mellitus and multiple therapeutic approaches of phytochemicals: Present status and future prospects. *Cur sci*, 2002; 83.
193. Havsteen B. Flavonoids- a class of natural products of high pharmacological potency. *Biochem pharmacol*, 1983; 32(7), 1141-1148.
194. Middleton E, Kandaswami C & Theoharides T. C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. *Pharmacol rev*, 2000; 52(4), 673-751.
195. Taylor A. Cataract: relationship between nutrition and oxidation. *J Am Coll Nutri*, 1993; 12(2), 138-146.
196. Taylor A. Nutritional influences on risk for cataract. *Int Ophthalmol Clin* , 2000;40(4), 17-49.
197. Patil B. S, Jayaprakasha G. K, Chidambara Murthy K. N & Vikram, A. Bioactive compounds: historical perspectives, opportunities, and challenges. *J agri food chem*, 2009. 57(18), 8142-8160.

198. Majumdar S & Srirangam R. Potential of the bioflavonoids in the prevention/treatment of ocular disorders. *J Pharm and Pharmacol*, 2010; 62(8), 951-965.
199. Kalt W, Hanneken A, Milbury P & Tremblay F. Recent Research on Polyphenolics in Vision and Eye Health†. *J agri food chem*, 2010; 58(7), 4001-4007.
200. Sanderson J, McLauchlan W. R & Williamson G. Quercetin inhibits hydrogen peroxide-induced oxidation of the rat lens. *Free Radical Biology and Medicine*, 1999; 26(5), 639-645.
201. Cornish K. M, Williamson G & Sanderson J. Quercetin metabolism in the lens: role in inhibition of hydrogen peroxide induced cataract. *Free Radical Biology and Medicine*, 2002; 33(1), 63-70.
202. Gayathri Devi V, Rooban B. N, Sasikala V, Sahasranamam V & Abraham A. Isorhamnetin-3-glucoside alleviates oxidative stress and opacification in selenite cataract in vitro. *Toxicology in vitro*, 2010; 24(6), 1662-1669.
203. Rooban B. N, Sasikala V, Sahasranamam V & Abraham A. Amelioration of selenite toxicity and cataractogenesis in cultured rat lenses by Vitex negundo. *Graefe's Arch Clin Exptl Ophthal*, 2011; 249(5), 685-692.



- 
204. Lu M. P, Wang R, Song X, Chibbar R, Wang X, Wu L & Meng Q. H. Dietary soy isoflavones increase insulin secretion and prevent the development of diabetic cataracts in streptozotocin-induced diabetic rats. *Nutri res*, 2008; 28(7), 464- 471.
205. Nakano M, Orimo N, Katagiri N, Tsubata M, Takahashi J & Van Chuyen, N. Inhibitory Effect of Astraxanthin Combined with Flavangenol® on Oxidative Stress Biomarkers in Streptozotocin-Induced Diabetic Rats. *Int J Vitam Nutr Res Suppl*, 2008; 78(45), 175-182.
206. Beyer-Meyers & Farnsworth 1979
207. Mohan M, Gupta S K, Agnihotri S, Joshi S, Uppal R K. Anticataract action of topical quercetin and myricetin in galactosemic rats. *Med Sci Res* (UK) 1988;16:685–686
208. Ramana B. V, Raju T. N, Kumar V. V & Reddy P. U. M. Defensive role of quercetin against imbalances of calcium, sodium, and potassium in galactosemic cataract. *Biol Trace Elem Res*, 2007; 119(1), 35-41.
209. Shearer T. R, Ma H, Fukiage C & Azuma M. Selenite nuclear cataract: review of the model. *Mol Vis*, 1997; 3(8).

- 
210. Gupta S. K, Selvan V K, Agrawal S S & Saxena R. Advances in pharmacological strategies for the prevention of cataract development. *Indian J Ophthalmol*, 2009; 57(3), 175.
211. Kyselova Z. Different experimental approaches in modelling cataractogenesis. *Interdiscip Toxicol*, 2010; 3(1), 3-14.
212. Lija Y, Biju P. G, Reeni A, Cibin T. R, Sahasranamam V & Abraham A. (). Modulation of selenite cataract by the flavonoid fraction of *Emilia sonchifolia* in experimental animal models. *Phytother Res*, 2006; 20(12), 1091-1095.
213. Fossen T, Pedersen A. T & Andersen Ø. M. Flavonoids from red onion (*Allium cepa*) *Phytochemistry*, 1998; 47(2), 281-285.
214. Miesan K. H & Mohamed S. Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants. *J Agric Food Chem*, 2001; 49(6), 3106-3112.
215. Javadzadeh A, Ghorbanihaghjo A, Bonyadi S, Rashidi M. R, Mesgari M, Rashtchizadeh N & Argani H. (). Preventive effect of onion juice on selenite-induced experimental cataract. *Indian J Ophthalmol*, 2009; 57(3), 185.
216. Thiagarajan G, Chandani S, Sundari C. S, Rao S. H., Kulkarni, A. V & Balasubramanian, D. Antioxidant properties of green and black tea,

- and their potential ability to retard the progression of eye lens cataract. *Exp eye res*, 2001; 73(3), 393-401.
217. Thiagarajan G, Chandani S, Harinarayana Rao S, Samuni A. M, Chandrasekaran K & Balasubramanian D. Molecular and cellular assessment of ginkgo biloba extract as a possible ophthalmic drug. *Exp eye res*, 2002; 75(4), 421-430.
218. Durukan, A. H, Evereklioglu C, Hurmeric V, Kerimoglu H, Erdurman C, Bayraktar M. Z & Mumcuoglu T. Ingestion of IH636 grape seed proanthocyanidin extract to prevent selenite-induced oxidative stress in experimental cataract. *J Cataract Refract Surg*, 2006; 32(6), 1041-1045.
219. Vibin M, Siva Priya S. G N. Rooban B, Sasikala V, Sahasranamam V & Abraham A. Broccoli regulates protein alterations and cataractogenesis in selenite models. *Curr eye res*, 2010 35(2), 99-107.
220. Ertekin M. V, Koçer I, Karşlıoğlu I, Taysi S, Gepdiremen A, Sezen O & Bakan, N. Effects of oral Ginkgo biloba supplementation on cataract formation and oxidative stress occurring in lenses of rats exposed to total cranium radiotherapy. *Jpn J Ophthalmol*, 2004; 48(5), 499-502.
221. Stefek M. Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract. *Interdiscip Toxicol*, 2011; 4(2), 69-77.

- 
222. Pietta P. G. Flavonoids as antioxidants. *J Nat Prod*, 2000; 63(7), 1035-1042.
223. Butkovic V, Klasinc L & Bors W. Kinetic study of flavonoid reactions with stable radicals. *J Agric Food Chem*, 2004; 52(10), 2816-2820.
224. Boots A. W, Haenen G. R & Bast A. Health effects of quercetin: from antioxidant to nutraceutical . *Eur J Clin Pharmacol*, 2008; 585(2), 325-337.
225. Bors W & Michel C. Chemistry of the antioxidant effect of polyphenols. *Ann N Y Acad Sci* , 2002; 957(1), 57-69.
226. Nijveldt R. J, Van Nood E, Van Hoorn D. E, Boelens P. G, Van Norren K & Van Leeuwen P. A. Flavonoids: a review of probable mechanisms of action and potential applications. *Am J clin nutri*, 2001; 74(4), 418-425.
227. Williams R. J, Spencer J. P & Rice-Evans C. Flavonoids: antioxidants or signalling molecules? *Free Radical Biology and Medicine*, 2004; 36(7), 838-849.
228. Matsuda H, Wang T, Managi H, Yoshikawa M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities. *Bioorganic and Med Chem*, 2003; 11; 5317-5323.

- 
229. Morimitsu Y, Yoshida K, Esaki S, Hirota A. Protein glycation inhibitors from thyme (*Thymus Vulgaris*). *Biosci Biotechnol Biochem*,1995;59(11): 2018–2021
230. Beaulieu L. P, Harris C. S, Saleem A, Cuerrier A, Haddad P. S, Martineau L. C & Arnason J.T. Inhibitory effect of the cree traditional medicine wiishichimanaanh (*Vaccinium vitis idaea*) on advanced glycation end product formation: identification of active principles. *Phytotherapy research*, 2010; 24(5), 741-747.
231. Wu C. H & Yen G. C. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts. *J agri food chem*, 2005; 53(8), 3167-3173.
232. Nagasawa T, Tabata N, Ito Y, Nishizawa N, Aiba Y & Kitts D. D. Inhibition of glycation reaction in tissue protein incubations by water soluble rutin derivative. *Mol cellular biochem* , 2003; 249(1-2), 3-10.
233. Costantino L, Rastelli G, Gamberini M. C & Barlocco D. Pharmacological approaches to the treatment of diabetic complications. *Expert Opinion on Therapeutic Patents*, 2000; 10(8), 1245-1262.

- 
234. Miyamoto S. Molecular modeling and structure-based drug discovery studies of aldose reductase inhibitors. *Chem-Bio Inform J*, 2002; 2, 74-85.
235. Suzen S & Buyukbingol E. Recent studies of aldose reductase enzyme inhibition for diabetic complications. *Curr med chem*, 2003; 10(15), 1329-1352.
236. Alexiou P, Pegklidou K, Chatzopoulou M, Nicolaou I & Demopoulos V. J. Aldose reductase enzyme and its implication to major health problems of the 21st century. *Curr med chem*, 2009; 16(6), 734-752.
237. Obrosova I. G, Maksimchyk Y, Pacher P, Agardh E, Smith M. L, El-Remessy, A. B & Agardh C. D. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina. *Intl J mol med*, 2010; 26(1), 135.
238. Varma, S. D, Mikuni, I & Kinoshita J. H. Flavonoids as inhibitors of lens aldose reductase. *Science*, 1975; 188(4194), 1215-1216.
239. Okuda J, Miwa I, Inagaki K, Horie T & Nakayama M. Inhibition of aldose reductases from rat and bovine lenses by flavonoids. *Biochemical pharmacology*, 1982; 31(23), 3807- 3822.

- 
240. Nakai N, Fujii Y, Kobashi K & Nomura K. Aldose reductase inhibitors: flavonoids, alkaloids, acetophenones, benzophenones, and spirohydantoins of chroman. *Arch of biochem and biophy*, 1985; 239(2), 491-496.
241. Jung S. H, Lee Y. S, Lee S, Lim S. S, Kim Y. S & Shin K. H. Isoflavonoids from the rhizomes of *Belamcanda chinensis* and their effects on aldose reductase and sorbitol accumulation in streptozotocin induced diabetic rat tissues. *Arch pharmacol res*, 2002; 25(3), 306-312.
242. Lee J, Kim N. H, Nam J. W, Lee Y. M, Jang D. S, Kim Y. S & Kim J. S. Scopoletin from the flower buds of *Magnolia fargesii* inhibits protein glycation, aldose reductase and cataractogenesis ex vivo. *Arch pharmacol res*, 2010 33(9), 1317-1323.
243. Saraswat M, Muthenna P, Suryanarayana P, Petrash J. M & Reddy G. B. Dietary sources of aldose reductase inhibitors: prospects for alleviating diabetic complications. *Asia Pac J Clin Nutr*, 2008; 17(4).
244. Karunanayake E.H, Welihinda J, Sirimanne S.R & Adorai G.S. Oral hypoglycaemic activity of some medicinal plants of Sri Lanka . *J Ethnopharmacol* , 1984; 11(2), 223-231.

245. Seema P. V, Sudha B, Padayatti P. S, Abraham A, Raghu K. G & Paulose C. S. Kinetic studies of purified malate dehydrogenase in liver of streptozotocin-diabetic rats and the effect of leaf extract of *Aegle marmelose* (L) Correa ex Roxb. *Ind J of exptl biol*, 1996; 34, 600-602.
246. Das U. K, De D, Chatterjee K, Mallick C, Bera T. K & Ghosh D. Antigonadal effect induced by hydro-methanolic extract of leaf of *Aegle mermelos* in male rat: effect of hCG co-administration. *J of Med Plants Res*, 2009 3(10), 728-735.
247. Jagetia G. C, Venkatesh P & Baliga M. S. Evaluation of the radioprotective effect of *Aegle marmelos* (L.) Correa in cultured human peripheral blood lymphocytes exposed to different doses of  $\gamma$  radiation: a micronucleus study. *Mutagenesis*, 2003; 18(4), 387-393.
248. Upadhya S, Shanbhag K. K, Suneetha G, Balachandra Naidu M & Upadhya S. A study of hypoglycemic and antioxidant activity of *Aegle marmelos* in alloxan induced diabetic rats. *Ind J Physiol Pharmacol*, 2004; 48(4), 476-480.
249. PTC Ponnachan, CS Paulose, KR Panikkar; Effect of leaf extract of *Aegle marmelos* in diabetic rats. *Indian J Exp Biol*, 1993; 31, 345-347



- 
250. Narendhirakannan R. T & Subramanian S. Biochemical evaluation of the protective effect of *Aegle marmelos* (L.), Corr. leaf extract on tissue antioxidant defense system and histological changes of pancreatic  $\beta$ -cells in streptozotocin-induced diabetic rats. *Drug Chem Toxicol*, 2010; 33(2), 120-130.
251. Drobiova H, Thomson M, Al-Qattan K, Peltonen-Shalaby R, Al-Amin, Z & Ali M. Garlic increases antioxidant levels in diabetic and hypertensive rats determined by a modified peroxidase method. *Evid Based Complement Alternat Med*, 2010;
252. Anwar M. M & Meki, A. R. Oxidative stress in streptozotocin-induced diabetic rats: effects of garlic oil and melatonin. *Comp Biochem Physiol A Mol Integr Physiol*, 2003; 135(4), 539-547.
253. Padiya, R., Khatua, T. N., Bagul, P. K., Kuncha, M., & Banerjee, S. K. Garlic improves insulin sensitivity and associated metabolic syndromes in fructose fed rats. *Nutr Metab (Lond)*, 2011; 8(1), 53.
254. Raju T. N, Kanth V. R & Lavanya K. Effect of methanolic extract of *Allium sativum* (AS) in delaying cataract in STZ-induced diabetic rats. *J Ocul Biol Dis Infor*, 2008; 1(1), 46-54.

- 
255. Eidi A, Eidi M & Esmaeili E. Antidiabetic effect of garlic (*Allium sativum* L.) in normal and streptozotocin-induced diabetic rats. *Phytomedicine*, 2006; 13(9), 624-629.
256. Zhao C & Shichi H. Prevention of acetaminophen-induced cataract by a combination of diallyl disulfide and N-acetylcysteine. *J Ocul Pharmacol Ther*, 1998; 14(4), 345-355.
257. Mathew PT, Augusti KT. Studies on the effect of allicin (diallyl disulphide-oxide) on alloxan diabetes Its Hypoglycaemic action and enhancement of serum insulin effect and glycogen synthesis. *Indian J Biochem Biophys* , 1973; 10: 209–212
258. Jain R. C & Vyas C. R. Garlic in alloxan-induced diabetic rabbits. *Am J clin nutri*, 1975, 28(7), 684-685.
259. Adachi Y, Yoshida J, Kodera Y, Katoh A, Takada J & Sakurai H. Bis (allixinato) oxovanadium (IV) complex is a potent antidiabetic agent: studies on structure-activity relationship for a series of hydroxypyrrone-vanadium complexes. *Journal of medicinal chemistry*, 2006; 49(11), 3251-3256.
260. Suryanarayana P, Saraswat M, Petrash J. M & Reddy G. B. *Emblica officinalis* and its enriched tannoids delay streptozotocin-induced

- 
- diabetic cataract in rats. 2007; Available from **digitalcommons.wustl.edu**
261. Puppala M, Ponder J, Suryanarayana P, Reddy G. B, Petrash J. M & LaBarbera, D. V. The isolation and characterization of  $\beta$ -glucogallin as a novel aldose reductase inhibitor from *Embllica officinalis*. *PloS one*, 2012; 7(4), e31399.
262. Rao G, Bhat S & Rao G. Antidiabetic and Antioxidant Efficacy of a Powdered Mixture of *Curcuma Longa* and *Embllica Officinalis* In Diabetic Rats In Comparison with Glyburide. 2013; Available from **webmedcentral.com**
263. Khan K. H. Roles of *Embllica officinalis* in medicine-A review. *Bot Res Int*, 2009; 2(4), 218-28.
264. Shrotri D. S, Kelkar M, Deshmukh V. K & Alman R. Investigations of the hypoglycaemic properties of *Vinca rosea*, *Cassia auriculata* and *Eugenia jambolana*. *Ind J Med Res*, 1963; 51.
265. Bansal R, Ahmad N & Kidwai J. R. Effects of oral administration of *Eugenia jambolana* seeds & chlorpropamide on blood glucose level & pancreatic cathepsin B in rat. *Indian J Biochem Biophys*, 1981; 18(5), 377.

266. Grover J. K, Vats V & Rathi S. S. Anti-hyperglycemic effect of *Eugenia jambolana* and *Tinospora cordifolia* in experimental diabetes and their effects on key metabolic enzymes involved in carbohydrate metabolism. *J Ethnopharmacol*, 2000; 73(3), 461-470.
267. Vikrant V, Grover J. K, Tandon N, Rathi S. S & Gupta N. Treatment with extracts of *Momordica charantia* and *Eugenia jambolana* prevents hyperglycemia and hyperinsulinemia in fructose fed rats. *J Ethnopharmacol*, 2001; 76(2), 139-143.
268. Rekha N, Balaji R & Deecarama M. Effect of aqueous extract of *Syzygium cumini* Pulp on antioxidant defense system in streptozotocin induced diabetic rats. *Iranian J Pharmacol & Ther*, 2008; 7(2), 137-145.
269. Ruan Z. P, Zhang L. L & Lin Y. M. Evaluation of the antioxidant activity of *Syzygium cumini* leaves. *Molecules*, 2008; 13(10), 2545-2556.
270. Karthic K, Kirthiram K. S, Sadasivam S, Thayumanavan B & Palvannan T. Identification of  $\alpha$ -amylase inhibitors from *Syzygium cumini* Linn seeds. *Indian J Exp Biol*, 2008; 46(9), 677-680.

271. Purohit A & Daradka H. M. M. Antidiabetic activity of *Szygium cumini* seeds extract in alloxan induced diabetic mice. *Hamdard medicus*, 2000; 43(4), 33-34.
272. Prince P, Menon V. P & Pari L. Hypoglycaemic activity of *Syzygium cumini* seeds: effect on lipid peroxidation in alloxan diabetic rats. *J Ethnopharmacol* 1998; 61(1), 1-7.
273. Bhat M, Zinjarde S. S, Bhargava S. Y, Kumar A. R & Joshi B. N. Antidiabetic Indian plants: a good source of potent amylase inhibitors. *Evid Based Complement Alternat Med*, 2011, 36.
274. Lowry O. H, Rosebrough N. J, Farr A. L & Randall R. J. Protein measurement with the Folin phenol reagent. *J biol chem*, 1951. 193(1), 265-275.
275. Kei Satoh. Serum lipid peroxide in cerebrovascular disorders determined by a new colorimetric method. *Clin Chim Acta*, 1978, 90.1: 37-43.
276. Marklund S & Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. *Eur J Biochem*, 1974; 47(3), 469-474.

277. Paglia D. E & Valentine W. N. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *J Lab Clin Med*, 1967, 70(1), 158-169.
278. Goldberg D. M & Spooner R. J. Glutathione reductase. *Meth enz anal*, 1983; 3, 258-265.
279. Hayman S & Kinoshita J. H. Isolation and properties of lens aldose reductase. *J Biol Chem*, 1965. 240(2), 877-882.
280. Truscott R. J & Augusteyn R. C. Oxidative changes in human lens proteins during senile nuclear cataract formation. *Biochim Biophys Acta (BBA)-Prot Struct*, 1977; 492(1), 43-52.
281. Charlton J. M & van Heyningen R. An investigation into the loss of proteins of low molecular size from the lens in senile cataract. *Exp eye res*, 1968; 7(1), 47-55.
282. Sheridan E. J & Zigman S. Fate of human lens soluble protein during cataractogenesis. *Exp eye res*, 1971; 12(1), 33-38.
283. Zhang W. Z & Augusteyn R. C. Ageing of glutathione reductase in the lens. *Exp eye res*, 1994; 59(1), 91-96.
284. Chihuailaf R. H, Contreras P. A & Wittwer F. G. Pathogenesis of oxidative stress: Consequences and evaluation in animal health. *Veterinaria México*, 2002; 33(3), 265-284.

- 
285. Heidland A, Sebekova K & Schinzel R. Advanced glycation end products and the progressive course of renal disease. *Am j kidney dis*, 2001; 38(4), S100-S106.
286. Fukaya Y, Nakazawa K, Okuda T & Iwata S. Effect of tannin on oxidative damage of ocular lens. *Jap J ophthal*, 1987, 32(2), 166-175.
287. Jain R. M & Bulakh P. M. Effect of ketoacids on H<sub>2</sub>O<sub>2</sub> induced cataract. *Ind J Clin Biochem*, 2003; 18(1), 91-95.
288. Özmen D, Özmen B, Erkin E, Güner İ, Habif S, Bayındır O & Onağ A. Lens superoxide dismutase and catalase activities in diabetic cataract. *Turk J Endocrin Metab*, 2000; 4(1), 1-4.
289. Arai K, Iizuka S, Tada Y, Oikawa K & Taniguchi N. Increase in the glucosylated form of erythrocyte Cu-Zn-superoxide dismutase in diabetes and close association of the nonenzymatic glucosylation with the enzyme activity. *Biochim Biophys Acta (BBA)-General Subjects*, 1987; 924(2), 292-296.
290. Maritim A. C, Moore B. H, Sanders R. A & Watkins J. B. Effects of melatonin on oxidative stress in streptozotocin-induced diabetic rats. *Int J toxicol*, 1999; 18(3), 161-166.
291. Sadi G, Yılmaz Ö & Güray T. Effect of vitamin C and lipoic acid on streptozotocin-induced diabetes gene expression: mRNA and protein

- expressions of Cu–Zn SOD and catalase. *Mol cell biochem*, 2008; 309(1-2), 109-116.
292. Sen C. K & Packer L. Antioxidant and redox regulation of gene transcription. *The FASEB journal*, 1996; 10(7), 709-720.
293. Strehlow K, Rotter S, Wassmann S, Adam O, Grohé C, Laufs K & Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. *Circ Res*, 2003; 93(2), 170-177.
294. Mayo J. C, Sainz R M, Antolin I, Herrera F, Martin V & Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. *Cell Mol Life Sci*, 2002; 59(10), 1706-1713.
295. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R & Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. *J Am Soc Nephrol*, 2003, 14(suppl 3), S250-S253.
296. Bhor V. M, Raghuram N & Sivakami S. Oxidative damage and altered antioxidant enzyme activities in the small intestine of streptozotocin-induced diabetic rats. *Int J biochem cell biol*, 2004; 36(1), 89-97.
297. Kakkar R, Kalra J, Mantha S. V & Prasad K. Lipid peroxidation and activity of antioxidant enzymes in diabetic rats. *Mol cell biochem*, 1995; 151(2), 113-119.



298. Dwivedi R. S & Pratap V. B. Alteration in glutathione metabolism during cataract progression. *Ophthalm res*, 1987; 19(1), 41-44.
299. Babizhayev M.A, Deyev A. I & Chernikov A. V. Peroxide-metabolizing systems of the crystalline lens. *Biochim Biophys Acta (BBA)-Molecular Basis of Disease*, 1992; 1138(1), 11-19.
300. Lou M. F, Dickerson J, Jaime E, Tung W. H, Wolfe J. K, Chylack J & Leo T. Correlation of nuclear color and opalescence with protein S-thiolation in human lenses. *Exp eye res*, 1999; 68(5), 547-552.
301. Rao P. V & Bhat K. S. Influence Dietary Riboflavin Deficiency on Lenticular Glutathione Redox Cycle, Lipid Peroxidation, and Free Radical Scavengers in the Rat. *J Clin Biochem Nutri*, 1989; 6(3), 195-204.
302. Lou M. F. Redox regulation in the lens. *Prog retin eye res*, 2003; 22(5), 657-682.
303. Matsunami T, Sato Y, Sato T, Ariga S, Shimomura T & Yukawa M. (). Oxidative stress and gene expression of antioxidant enzymes in the streptozotocin-induced diabetic rats under hyperbaric oxygen exposure. *Int J clin exptl pathol*, 2010; 3(2), 177.

- 
304. Sadi G & Güray T. Gene expressions of Mn-SOD and GPx-1 in streptozotocin-induced diabetes: effect of antioxidants. *Mol cell biochem*, 2009;327(1-2), 127-134.
305. Tirosh A, Potashnik R, Bashan N & Rudich A. Oxidative Stress Disrupts Insulin-induced Cellular Redistribution of Insulin Receptor Substrate-1 and Phosphatidylinositol 3-Kinase in 3T3-L1 Adipocytes A Putative Cellular Mechanism For Impaired Protein Kinase B Activation And Glut4 Translocation. *J Biol Chem*, 1999; 274(15), 10595-10602.
306. Kinoshita J. H & Nishimura C. The involvement of aldose reductase in diabetic complications. *Diabetes metab rev*, 1988; 4(4), 323-337.
307. Hwang Y. C, Kaneko M, Bakr S, Liao H, Lu Y, Lewis E. R & Ramasamy R. Central role for aldose reductase pathway in myocardial ischemic injury. *The FASEB journal*, 2004; 18(11), 1192-1199.
308. Busik J. V, Hootman S. R, Greenidge C. A & Henry D. N. Glucose-specific regulation of aldose reductase in capan-1 human pancreatic duct cells in vitro. *J Clin Invest*, 1997; 100(7), 1685.
309. Jedziniak J. A, Chylack L. T, Cheng H. M, Gillis M. K, Kalustian A. A & Tung W. H. The sorbitol pathway in the human lens: aldose reductase and polyol dehydrogenase. *Invest ophthalmol vis sci* , 1981; 20(3), 314-326.

- 
310. Cheng H. M & Chylack L. T. Thiol oxidation in the crystalline lens. I. The rate-limiting role of hexokinase in aging rat and human lenses. *Invest ophthalmol vis sci*, 1980; 19(5), 522-528.
311. Harding J. J. Can drugs or micronutrients prevent cataract? *Drugs aging*, 2001; 18(7), 473-486.
312. Jacques P. F, Taylor A, Hankinson S. E, Willett W. C, Mahnken B, Lee Y & Lahav M. Long-term vitamin C supplement use and prevalence of early age-related lens opacities. *Am J clin nutri*, 1997; 66(4), 911-916.
313. Bates C. J, Chen S. J, Macdonald A & Holden R. Quantitation of vitamin E and a carotenoid pigment in cataractous human lenses, and the effect of a dietary supplement. *Int J vit nutri res*. 1995; 66(4), 316-321.
314. Knekt P, Heliövaara M, Rissanen A, Aromaa A & Aaran R. K. Serum antioxidant vitamins and risk of cataract. *BMJ*, 1992; 305(6866), 1392.
315. Borenshtein D, Ofri R, Werman M, Stark A, Tritschler H. J, Moeller W & Madar Z. Cataract development in diabetic sand rats treated with  $\alpha$ -lipoic acid and its  $\gamma$ -linolenic acid conjugate. *Diabetes metab res rev*, 2001; 17(1), 44-50.

316. Devamanoharan P. S, Henein M, Ali, A. H & Varma S. D. Attenuation of sugar cataract by ethyl pyruvate. *Mol cell biochem*, 1999; 200(1-2), 103-109.
317. Zhao W, Devamanoharan P. S & Varma S. D. Fructose induced deactivation of glucose-6-phosphate dehydrogenase activity and its prevention by pyruvate: implications in cataract prevention. *Free radical research*, 1998; 29(4),315-320.
318. Zhao W, Devamanoharan P. S, Henein M, Ali A. H & Varma S. D. Diabetes-induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate. *Diabetes Obes Metab*, 2000; 2(3), 165-174.
319. Chasan-Taber L, Willett W. C, Seddon J. M, Stampfer M. J, Rosner B, Colditz G. A & Hankinson S. E. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. *Am J clin nutri*, 1999; 70(4), 509-516.
320. Blakytyn R & Harding J. J. Glycation (non-enzymic glycosylation) inactivates glutathione reductase. *Biochem. J*, 1992; 288, 303-307.
321. Varma S. D, Devamanoharan P. S & Ali A. H. Formation of advanced glycation end (AGE) products in diabetes: Prevention by pyruvate and a-keto glutarate. *Mol cell biochem*, 1997; 171(1-2), 23-28.

- 
322. Packer, L.  $\alpha$ -Lipoic acid: a metabolic antioxidant which regulates NF- $\kappa$ B signal transduction and protects against oxidative injury. *Drug metab rev*, 1998; 30(2), 245-275.
323. Suzuki Y. J, Aggarwal B. B & Packer L. ().  $\alpha$ -Lipoic acid is a potent inhibitor of NF- $\kappa$ B activation in human T cells. *Biochem biophys res commun*, 1992; 189(3), 1709-1715.
324. Costantino L, Rastelli G, Gamberini M. C, Vinson J. A, Bose P, Iannone A & Albasini A. 1-Benzopyran-4-one antioxidants as aldose reductase inhibitors. *J med chem*, 1999; 42(11), 1881-1893.
325. Hamada Y, Nakamura J, Naruse K, Komori T, Kato K, Kasuya Y & Hotta N . Epalrestat, an aldose reductase inhibitor, reduces the levels of Nepsilon-(carboxymethyl) lysine protein adducts and their precursors in erythrocytes from diabetic patients. *Diabetes Care*, 2000; 23(10), 1539-1544.
326. Ao S, Shingu Y, Kikuchi C, Takano Y, Nomura K, Fujiwara T & Yamaguchi I. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. *Metabolism*, 1991; 40(1), 77-87.
327. Beyer-Mears A & Cruz E. Reversal of diabetic cataract by sorbinil, an aldose reductase inhibitor. *Diabetes*, 1985; 34(1), 15-21.

- 
328. Jang, D. S, Yoo N. H, Kim N. H, Lee Y. M, Kim C. S, Kim J & Kim, J. S. (). 3, 5-Di-O-caffeoyl-epi-quinic acid from the leaves and stems of *Erigeron annuus* inhibits protein glycation, aldose reductase, and cataractogenesis. *Biol pharma bull* , 2009; 33(2), 329-333.
329. Krushna G. S. S, Kareem M. A, Reddy, V. D, Padmavathi P. Hussain S. A & Kodidhela L. D. Aegle marmelos fruit extract attenuates isoproterenol-induced oxidative stress in rats. *J clin biochem nutri*, 2012, 50(3), 199.
330. Ravi K, Ramachandran B & Subramanian S. Effect of *Eugenia Jambolana* seed kernel on antioxidant defense system in streptozotocin-induced diabetes in rats. *Life sciences*, 2004; 75(22), 2717-2731.
331. Afify A. M. R Fayed S. A, Shalaby E. A & El-Shemy H. A. *Syzygium cumini* (pomposia) active principles exhibit potent anticancer and antioxidant activities. *Afr J Pharm Pharmacol*, 2011; 5, 948-956.
332. Pozharitskaya O. N, Ivanova S. A, Shikov A. N & Makarov V. G. Separation and evaluation of free radical-scavenging activity of phenol components of *Emblica officinalis* extract by using an HPTLC–DPPH• method. *J sep sci*, 2007; 30(9), 1250-1254.
333. Halliwell B. Vitamin C: poison, prophylactic or panacea? *Trends biochem sci*, 1999; 24(7), 255-259.

334. Young I. S, Torney J. J & Trimble E. R. The effect of ascorbate supplementation on oxidative stress in the streptozotocin diabetic rat. *Free Radic Biol Med*, 1992; 13(1), 41-46.
335. Varma S.D & Richards R. D. Ascorbic acid and the eye lens. *Ophthalmol*, 1988, 20(3), 164-173.
336. Harman D. The aging process: major risk factor for disease and death. *Proc Nat Acad Sci*, 1991; 88(12), 5360-5363.
337. Arunabh Bhattacharya, Ghosal C, S & Bhattacharya S. K. Antioxidant activity of active tannoid principles of *Emblica officinalis* (amla). *Ind J Exp Biol*, 1999; 37, 676-680.
338. Devi K. U, Vanitha V, Vijayalakshmi K & Tilton F. Determination of Bioactive Components Of *Aegle Marmelos* L. Leaves By GC-MS Analysis. *Ind Streams Res J*, 2011; 1(11).
339. Sharma S. Impact of Ace Inhibitors on the Morphological and Biochemical Aspects of Experimental Cataract: An In Vitro and In Vivo Study. 2011, *PhD Thesis*
340. Javadzadeh A, Ghorbanihaghjo A, Arami S, Rashtchizadeh N, Mesgari M, Rafeey M & Omid Y. Prevention of selenite-induced cataractogenesis in Wistar albino rats by aqueous extract of garlic. *J Ocul Pharmacol Ther*, 2009; 25(5), 395-400.

341. Garg M. C & Bansal D. D. Protective antioxidant effect of vitamins C and E in streptozotocin induced diabetic rats. *Ind J exp biol*, 2000; 38(2), 101-104.
342. Ranganathan S, Krempf M, Feraille E & Charbonnel B. Short term effect of an aldose reductase inhibitor on urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) in type 1 diabetic patients with incipient nephropathy. *Diab metab*, 1992; 19(2), 257-261.
343. Passariello N, Sepe J, Marrazz G, De Cicco A, Peluso A, Plsano M. C. A & D'Onofrio F. Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. *Diabetes Care*, 1993; 16(5), 789-795.
344. Handelsman D. J & Turtle J. R. Clinical trial of an aldose reductase inhibitor in diabetic neuropathy. *Diabetes*, 1981; 30(6), 459-464.
345. Jaspan J, Herold K, Maselli R & Bartkus C. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. *The Lancet*, 1983; 322(8353), 758-762.
346. Jaspan J. B, Towle V. L, Maselli R & Herold K. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. *Metabolism*, 1986; 35(4), 83-92.



- 
347. Srivastava S. K, Petrash J. M, Sadana I. J, Ansari N. H & Partridge C. A. Susceptibility of aldehyde and aldose reductases of human tissues to aldose reductase inhibitors. *Curr eye res*, 1982; 2(6)
348. Srivastava S. K & Ansari N. H. Prevention of sugar-induced cataractogenesis in rats by butylated hydroxytoluene. *Diabetes*, 1988; 37(11), 1505-1508.407-410.
349. Srivastava S, Liu S. Q, Conklin D. J, Zacarias A, Srivastava S. K & Bhatnagar, A. Involvement of aldose reductase in the metabolism of atherogenic aldehydes. *Chem biol interac*, 2001; 130, 563-571.
350. Srivastava S, Spite M. Trent J. O, West M. B, Ahmed Y & Bhatnagar A. Aldose reductase-catalyzed reduction of aldehyde phospholipids. *J Biol Chem*, 2004; 279(51), 53395-53406.
351. Ramana K. V, Friedrich B, Bhatnagar A & Srivastava S. K. Aldose reductase mediates cytotoxic signals of hyperglycemia and TNF- $\alpha$  in human lens epithelial cells. *The FASEB Journal*, 2003; 17(2), 315-317.
352. Kotowaroo M I, Mahomoodally M F, Gurib-Fakim A and Subratty AH. "Screening of traditional antidiabetic medicinal plants of Mauritius for possible  $\alpha$ -amylase inhibitory effects in vitro," *Phyto Res*, 2006; vol. 20, no. 3,228– 231.

353. Tsai S. J, Chiu C. P, Yang H. T & Yin M. C. s-Allyl cysteine, s-ethyl cysteine, and s-propyl cysteine alleviate  $\beta$ -amyloid, glycation, and oxidative injury in brain of mice treated by D-galactose. *J Agri food chem*, 2011; 59(11), 6319-6326.
354. Gacche R. N & Dhole N. A. Profile of aldose reductase inhibition, anti-cataract and free radical scavenging activity of selected medicinal plants: an attempt to standardize the botanicals for amelioration of diabetes complications. *Food and Chem Toxicol*, 2011; 49(8), 1806-1813.
355. Sankeshi V, Anil Kumar P, Ravindar Naik R, Sridhar G, Praveen Kumar M, Hara Gopal V. V & Naga Raju T. Inhibition of aldose reductase by *Aegle marmelos* and its protective role in diabetic cataract. *J ethnopharmacol*, 2013; 149(1), 215-221.